Supplementary Table S1. bDMARDs intake over time

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | y0 (n=96) | y1 (n=92) | y2 (n=88) | y3 (n=96) |
| Total(n=96) | Full regimen | 59 (61.5) | 38 (41.3) | 37 (42.0) | 36 (37.5) |
| Tapered regimen | 21 (21.9) | 34 (37.0) | 26 (29.5) | 29 (30.2) |
| No bDMARD because of remission | 12 (12.5) | 11 (12.0) | 15 (17.0) | 11 (11.5) |
| Switch because of inefficacy or relapse  | 4 (4.2) | 9 (9.8) | 10 (11.4) | 20 (20.8) |
| Initial M-arm(n=52) | Full regimen | 50 (96.2) | 25 (51.0) | 22 (44.9) | 23 (44.2) |
| Tapered regimen | 0 (0) | 17 (34.7) | 15 (30.6) | 15 (28.8) |
| No bDMARD because of remission | 0 (0) | 2 (4.1) | 6 (12.2) |  3 (5.8) |
| Switch because of inefficacy or relapse  | 2 (3.8) | 5 (10.2) | 6 (12.2) | 11 (21.2) |
| Initial S-arm(n=44) | Full regimen | 9 (20.5) | 13 (30.2) | 15 (38.5) | 13 (29.5) |
| Tapered regimen | 21 (47.7) | 17 (39.5) | 11 (28.2) | 14 (31.8) |
| No bDMARD because of remission | 12 (27.3) | 9 (20.9) | 9 (23.1) | 8 (18.2) |
| Switch because of inefficacy or relapse  | 2 (4.5) | 4 (9.3) | 4 (10.3) | 9 (20.5) |

Data are mean ± SD or n (%).

bDMARD, biological disease-modifying anti-rheumatic drug; M-arm, maintenance arm; S-arm, spacing arm; y0, start of the long-term observational study. y1, first data collection point 1 year after the end of STRASS; y2, second data collection point two years after the end of STRASS; y3, third data collection point three years after the end of STRASS